| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $7 to $6.
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $16...
Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (Nasdaq: BMEA), a clinical-stage diabe...
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.2...
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $16 price target.
Biomea Fusion reported favorable safety for icovamenib in a 52-week diabetes study, alongside a $25 million public offering.
